Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival
Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival
复制标题
DOI：
10.1002/path.1740
复制
发表时间：
2005-04-01
影响因子：
7.3
通讯作者：
Fox, SB
中科院分区：
文献类型：
--
作者：
Campo, L;Turley, H;Fox, SB
血管生成素是一种14.2kD的多肽，最初被认为具有血管生成活性，现在越来越多地被认为在生理和病理条件下都具有多种生物学作用。在乳腺癌中，有一些相互矛盾的研究质疑血管生成素的作用。本文报道了239例乳腺浸润性癌从正常乳腺组织向导管原位癌和浸润性癌转化过程中血管生成素的表达模式，以及血管生成素水平与标准临床病理参数、低氧诱导因子-1α及其靶基因DEC-1的相关性。结果表明，与正常乳腺组织相比，原位癌和浸润性癌组织中血管生成素在胞浆和胞核中的表达均显著上调；浸润性癌中血管生成素的表达与高分级(p=0.03)、雌激素受体(ER)阳性状态(p=0.01)、低氧诱导因子-1α(p=0.001)和DEC1(p=0.001)呈显著正相关，而与患者年龄(p=0.80)、肿瘤大小(p=0.25)、淋巴结状况(p=0.69)、表皮生长因子受体(p=0.56)和微血管密度(p=0.32)。按血管生成素表达分层的患者在无复发(P=0.26)或总生存率(P=0.63)方面没有差异。这项研究表明，血管生成素可能在乳腺癌的进展中起重要作用，并且通过它与ER的关系，它可能是他莫昔芬的靶点。版权所有(C)2005年大不列颠和爱尔兰病理学会。作者：John Wiley&Sons，Ltd.
Angiogenin, a 14.2 kD polypeptide that was originally noted for its angiogenic activity, is now increasingly recognized to have a multiplicity of biological roles in both physiological and pathological conditions. In breast cancer, there are conflicting studies questioning the role of angiogenin. Here, the pattern of expression of angiogenin during the transition from normal breast tissue to ductal carcinoma in situ and invasive carcinoma is reported together with the correlates between the level of angiogenin in 239 invasive carcinomas and standard clinicopathological parameters, hypoxia-inducible factor (HIF)-1 alpha and the HIF-1 alpha target gene DEC-1. This study shows that angiogenin expression is up-regulated in the cytoplasmic and nuclear compartments in in situ carcinoma and invasive carcinoma compared with normal breast tissue and that angiogenin expression in invasive carcinomas is significantly positively associated with high tumour grade (p = 0.03), positive oestrogen receptor (ER) status (p = 0.01), HIF-1 alpha (p = 0.001) and DEC 1 (p = 0.001), but not with patient age (p = 0.8), tumour size (p = 0.25), lymph node status (p = 0.69), epidermal growth factor receptor (p = 0.56) or microvessel density (p = 0.32). No difference in relapse-free (P = 0.26) or overall (p = 0.63) survival was observed in patients stratified by angiogenin expression. This study suggests that angiogenin may be important in breast cancer progression and that, through its relationship with ER, it may be a target for tamoxifen. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.